Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Seniors with DLBCL may benefit from Ga101-miniCHOP combo

11 Jan 2020

The combination obinutuzumab (Ga101) with the attenuated CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone; miniCHOP) is safe and effective for elderly patients with diffuse large B-cell lymphoma (DLBCL) who are unfit to receive the full-dose immunochemotherapy, a new study has found. However, the new regimen does not seem to be posed to challenge current treatment standards.

Thirty-three elderly patients with DLBCL (median age, 82 years; 55 percent male) were enrolled and given six courses of the Ga101-miniCHOP treatment regimen. Patients were deemed unfit for the complete course according to the simplified Comprehensive Geriatric Assessment. Treatment response rate was the primary outcome of the study, and safety was also assessed.

A total of 228 cycles were delivered, and 27 participants completed all six courses. Treatment interruptions were due to adverse events and lack of response.

Two patients suffered from infections, both leading to discontinuations. Hepatic toxicity and worsening performance status were other adverse events reported. After a median follow-up of 16 months, lymphoma had progressed in 18 patients. Ten patients died; nine were due to disease progression and one was because of an adverse event.

The 2-year progression-free and overall survival rates were 49 percent and 68 percent, respectively. A total of 14 patients showed complete treatment response, yielding a rate of 42 percent. Partial response was observed in eight participants (24 percent), while ten had stable or progressive disease (30 percent).

Despite decent response rates, “study accrual was interrupted due to the very low probability of demonstrating the initial study hypothesis that Ga101-miniCHOP could improve results of historical data obtained with rituximab-miniCHOP in this group of patients,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.